Literature DB >> 18639599

Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults.

Meng Chen1, Francis Ssali, Maureen Mulungi, Peter Awio, Hiroyuki Yoshimine, Reiki Kuroki, Akitsugu Furumoto, Susumu Tanimura, Cissy Kityo, Tsuyoshi Nagatake, Peter Mugyenyi, Kazunori Oishi.   

Abstract

The levels of IgG determined by ELISA may have limited relevance in human immunodeficiency virus (HIV)-infected adults because of non-functional antibodies. 58 HIV-1-infected and 29 HIV-uninfected Ugandan adults were immunized with conjugate vaccine (CV) followed by polysaccharide vaccine (PV) after a 2-month interval, and the opsonophagocytic killing (OPK) titers against serotype 4 or 14 pneumococcal strains as well as the levels of serotype-specific IgG in sera were determined. Significant increases were found in the OPK titers and IgG levels for both serotypes after CV vaccination irrespective of HIV status. Increases in IgG levels and OPK titers were largely dependent on the CD4(+) cell counts, except for increases in the IgG levels for serotype 4. The proportions with serum OPK titer equal to or greater than 8 were 0-4.3% for serotype 4 and 26.7-42.9% for serotype 14 before vaccination, but the proportions increased up to 43.3-86.2% for serotype 4 and 63.3-96.6% for serotype 14 in all three groups 2 months after CV vaccination. The serum OPK titers remained at levels higher than the pre-vaccination level for at least 8 months after CV vaccination. A single dose of CV could afford some protective immunity in HIV-infected African adults before the introduction of antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18639599     DOI: 10.1016/j.vaccine.2008.06.093

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults in the era of highly active antiretroviral therapy: analysis stratified by CD4 T-cell count.

Authors:  Joon Young Song; Hee Jin Cheong; Ji Yun Noh; Min Joo Choi; Jin Gu Yoon; Woo Joo Kim
Journal:  Hum Vaccin Immunother       Date:  2019-08-23       Impact factor: 3.452

2.  Association of time since pneumococcal polysaccharide vaccine receipt and CD4 count with antibody response to the 13-valent pneumococcal conjugate vaccine in HIV-infected adults.

Authors:  Alexandria E-B Rossheim; Anna Marie P Young; Julia Siik; Tina D Cunningham; Stephanie B Troy
Journal:  Hum Vaccin Immunother       Date:  2016-05-12       Impact factor: 3.452

3.  Single-Dose 13-Valent Conjugate Pneumococcal Vaccine in People Living With HIV - Immunological Response and Protection.

Authors:  Juliette Romaru; Mathilde Bahuaud; Gauthier Lejeune; Maxime Hentzien; Jean-Luc Berger; Ailsa Robbins; Delphine Lebrun; Yohan N'Guyen; Firouzé Bani-Sadr; Frédéric Batteux; Amélie Servettaz
Journal:  Front Immunol       Date:  2021-12-20       Impact factor: 7.561

Review 4.  Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.

Authors:  Kuan-Yeh Lee; Mao-Song Tsai; Kuang-Che Kuo; Jen-Chih Tsai; Hsin-Yun Sun; Aristine C Cheng; Sui-Yuan Chang; Chen-Hsiang Lee; Chien-Ching Hung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Immunogenicity and safety after the third vaccination with the 23-valent pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease.

Authors:  Nobuharu Ohshima; Yukihiro Akeda; Hideaki Nagai; Kazunori Oishi
Journal:  Hum Vaccin Immunother       Date:  2020-02-12       Impact factor: 3.452

Review 6.  Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals.

Authors:  Marta C Nunes; Shabir A Madhi
Journal:  Hum Vaccin Immunother       Date:  2012-02-01       Impact factor: 3.452

7.  Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.

Authors:  As'ad E Bhorat; Shabir A Madhi; France Laudat; Vani Sundaraiyer; Alejandra Gurtman; Kathrin U Jansen; Daniel A Scott; Emilio A Emini; William C Gruber; Beate Schmoele-Thoma
Journal:  AIDS       Date:  2015-07-17       Impact factor: 4.177

Review 8.  Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part I.

Authors:  Nancy F Crum-Cianflone; Eva Sullivan
Journal:  Infect Dis Ther       Date:  2017-08-04

9.  Long-term immune responses and comparative effectiveness of one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-positive adults in the era of combination antiretroviral therapy.

Authors:  Aristine Cheng; Sui-Yuan Chang; Mao-Song Tsai; Yi-Ching Su; Wen-Chun Liu; Hsin-Yun Sun; Chien-Ching Hung
Journal:  J Int AIDS Soc       Date:  2016-01-29       Impact factor: 5.396

10.  Theory and strategy for Pneumococcal vaccines in the elderly.

Authors:  Ho Namkoong; Makoto Ishii; Yohei Funatsu; Yoshifumi Kimizuka; Kazuma Yagi; Takahiro Asami; Takanori Asakura; Shoji Suzuki; Testuro Kamo; Hiroshi Fujiwara; Sadatomo Tasaka; Tomoko Betsuyaku; Naoki Hasegawa
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.